|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...1314151617181920212223...4041» |
- Trial completion, Enrollment change, Trial primary completion date: The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS) (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=2, Completed, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Completed | N=15 --> 2 | Trial primary completion date: Sep 2014 --> Dec 2014
- | Trial completion, Enrollment change, Trial primary completion date: Multiple Sclerosis and Progressive Resistance Training (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=35, Completed, Sponsor: University of Aarhus
Recruiting --> Completed | N=15 --> 2 | Trial primary completion date: Sep 2014 --> Dec 2014 Active, not recruiting --> Completed | N=80 --> 35 | Trial primary completion date: Aug 2013 --> Jan 2014
- | Tysabri (natalizumab) / Biogen, Royalty
Trial completion, Enrollment change: The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=45, Completed, Sponsor: University of South Florida
Active, not recruiting --> Completed | N=80 --> 35 | Trial primary completion date: Aug 2013 --> Jan 2014 Recruiting --> Completed | N=30 --> 45
- Trial primary completion date: Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=108, Recruiting, Sponsor: University Hospital, Lille
Recruiting --> Completed | N=30 --> 45 Trial primary completion date: Apr 2014 --> Feb 2015
- GZ402668 / Sanofi
Enrollment open: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2014
P1, N=48, Recruiting, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Apr 2014 --> Feb 2015 Not yet recruiting --> Recruiting
- Clinical: Step it Up: An Exercise and Behaviour Change Programme for People With Multiple Sclerosis (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=72, Recruiting, Sponsor: University of Limerick
- ursodeoxycholic acid / Generic mfg.
Trial completion, Enrollment change: TUDCA-ALS: Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Nov 28, 2014
P2, N=34, Completed, Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=26 --> 34
- ||| Clinical: Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=750, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
- Enrollment open: Developing and Testing a Comprehensive MS Spasticity Management Program (clinicaltrials.gov) - Nov 25, 2014
P2, N=50, Enrolling by invitation, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed | N=26 --> 34 Not yet recruiting --> Enrolling by invitation
- ||| Betaseron (IFN-β-1b) / Bayer
Enrollment open, Adherence: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=450, Recruiting, Sponsor: Bayer
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- |||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment open: RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate (clinicaltrials.gov) - Nov 25, 2014
P4, N=90, Recruiting, Sponsor: EMD Serono
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion, Enrollment change: FARMS-2: Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior (clinicaltrials.gov) - Nov 25, 2014
P1/2, N=37, Completed, Sponsor: University of Illinois at Urbana-Champaign
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=60 --> 37
- Biomarker, Enrollment closed: Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Nov 24, 2014
P=N/A, N=17, Active, not recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed | N=60 --> 37 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open, P1 data, MRI: A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients (clinicaltrials.gov) - Nov 24, 2014
P1, N=12, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Myrbetriq (mirabegron) / Astellas
Enrollment change: Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients (clinicaltrials.gov) - Nov 24, 2014
P2/3, N=144, Enrolling by invitation, Sponsor: Lawson Health Research Institute
Not yet recruiting --> Recruiting N=72 --> 144
- fingolimod / Generic mfg.
Enrollment closed: Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=20, Active, not recruiting, Sponsor: Stony Brook University
N=72 --> 144 Recruiting --> Active, not recruiting
- | Trial completion, Enrollment change, Trial primary completion date: Mindfulness Based Stress Reduction in Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 20, 2014
P=N/A, N=31, Completed, Sponsor: Stony Brook University
Recruiting --> Active, not recruiting Recruiting --> Completed | N=69 --> 31 | Trial primary completion date: Nov 2011 --> Apr 2013
- Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment open: Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif (clinicaltrials.gov) - Nov 20, 2014
P1, N=30, Recruiting, Sponsor: Biogen Idec
Recruiting --> Completed | N=69 --> 31 | Trial primary completion date: Nov 2011 --> Apr 2013 Not yet recruiting --> Recruiting
- | olesoxime (TRO19622) / Roche
Trial completion: Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. (clinicaltrials.gov) - Nov 20, 2014
P1, N=44, Completed, Sponsor: Trophos
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Grupo Insud, Biocodex, Kuhnil Pharma
Trial primary completion date: Efficacy and Safety of Circadin (clinicaltrials.gov) - Nov 19, 2014
P3, N=120, Recruiting, Sponsor: Neurim Pharmaceuticals Ltd.
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Aug 2017
- Trial initiation date, Trial primary completion date, Immunomodulating: IMODALS: Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 (clinicaltrials.gov) - Nov 19, 2014
P1/2, N=24, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Trial primary completion date: Oct 2014 --> Aug 2017 Initiation date: Oct 2014 --> Jan 2015 | Trial primary completion date: Oct 2015 --> Jan 2016
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
New P1 trial: Mass Balance Study of MT-1303 (clinicaltrials.gov) - Nov 19, 2014
P1, N=9, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment change, Trial withdrawal: Frequency: Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (clinicaltrials.gov) - Nov 17, 2014
P4, N=0, Withdrawn, Sponsor: Biogen Idec
Initiation date: Oct 2014 --> Jan 2015 | Trial primary completion date: Oct 2015 --> Jan 2016 N=1200 --> 0 | Not yet recruiting --> Withdrawn
- Vitaros (alprostadil + novel excipient) / Seelos Therap
Enrollment open: Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Nov 17, 2014
P2, N=45, Recruiting, Sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
N=1200 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- ||||| Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment closed, Trial primary completion date: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) - Nov 17, 2014
P3, N=200, Active, not recruiting, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015
- Clinical: SOCOG-MS: Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients (clinicaltrials.gov) - Nov 14, 2014
P=N/A, N=35, Not yet recruiting, Sponsor: University Hospital, Bordeaux
- Clinical: DIMMISI: Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS (clinicaltrials.gov) - Nov 14, 2014
P=N/A, N=144, Recruiting, Sponsor: Niguarda Hospital
- || Trial primary completion date: SCI-COG: Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=120, Recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Nov 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Trial completion, Enrollment change: NEO: An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=154, Completed, Sponsor: Merck KGaA
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | N=254 --> 154
- |||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion, Trial primary completion date: Dose-finding Study of MT-1303 (clinicaltrials.gov) - Nov 12, 2014
P2, N=415, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed | N=254 --> 154 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jul 2014
- Clinical: Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=40, Recruiting, Sponsor: University Hospital of Ferrara
- New P1 trial: A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Nov 12, 2014
P1, N=25, Not yet recruiting, Sponsor: Massachusetts General Hospital
- Clinical: Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis (clinicaltrials.gov) - Nov 11, 2014
P=N/A, N=32, Completed, Sponsor: University of Deusto
- Enrollment closed: Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Nov 7, 2014
P1/2, N=30, Active, not recruiting, Sponsor: Iniciativa Andaluza en Terapias Avanzadas - Fundación Pública Andaluza Progreso y Salud
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jul 2014 Recruiting --> Active, not recruiting
- ||||||| everolimus / Generic mfg.
Trial completion: Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) (clinicaltrials.gov) - Nov 6, 2014
P3, N=118, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Clinical: Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery (clinicaltrials.gov) - Nov 5, 2014
P=N/A, N=450, Not yet recruiting, Sponsor: Biogen Idec
- ||| plovamer (CO-14) / EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date: EMR200575-001: Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) (clinicaltrials.gov) - Nov 5, 2014
P2, N=255, Active, not recruiting, Sponsor: EMD Serono
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=550 --> 255 | Trial primary completion date: Nov 2016 --> Feb 2015
- |||||| dalfampridine / Generic mfg.
Enrollment open: ENHANCE: Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (clinicaltrials.gov) - Nov 4, 2014
P3, N=590, Recruiting, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting | N=550 --> 255 | Trial primary completion date: Nov 2016 --> Feb 2015 Not yet recruiting --> Recruiting
- Trial completion, Enrollment change, Trial primary completion date: FFF: Pilot Study of Free From Falls Program in Multiple Sclerosis (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=13, Completed, Sponsor: Oregon Health and Science University
Not yet recruiting --> Recruiting Recruiting --> Completed | N=36 --> 13 | Trial primary completion date: Apr 2014 --> Sep 2014
- | GZ402668 / Sanofi
New P1 trial: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Nov 4, 2014
P1, N=48, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company
- New P2 trial: Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 3, 2014
P2, N=30, Active, not recruiting, Sponsor: Universidad Austral de Chile
- |||| Uptravi (selexipag) / J&J, Nippon Shinyaku
Enrollment open: Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Oct 31, 2014
P2, N=70, Recruiting, Sponsor: Actelion
Recruiting --> Completed | N=36 --> 13 | Trial primary completion date: Apr 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- | propranolol / Generic mfg.
Trial initiation date, Trial primary completion date: STBETA: Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers (clinicaltrials.gov) - Oct 30, 2014
P2, N=15, Not yet recruiting, Sponsor: University Hospital, Bordeaux
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Nov 2014 | Trial primary completion date: Mar 2016 --> Nov 2016
- Clinical: Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc) (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Echosense Ltd.
- Tysabri (natalizumab) / Biogen, Royalty
IO biomarker: Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=40, Recruiting, Sponsor: University Hospital, Basel, Switzerland
- ||||||| Avonex (recombinant IFN-β-1a) / Biogen, Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion, Monotherapy: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 28, 2014
P3, N=1841, Completed, Sponsor: Biogen Idec
Initiation date: Mar 2014 --> Nov 2014 | Trial primary completion date: Mar 2016 --> Nov 2016 Active, not recruiting --> Completed
- Clinical: Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis (clinicaltrials.gov) - Oct 27, 2014
P=N/A, N=400, Recruiting, Sponsor: Dr. med. Micha Loebermann
- imatinib / Generic mfg.
Phase classification: A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis (clinicaltrials.gov) - Oct 27, 2014
P1/2, N=20, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Phase classification: P=N/A --> P1/2
- | everolimus / Generic mfg.
Enrollment closed, Trial primary completion date: Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) (clinicaltrials.gov) - Oct 24, 2014
P2, N=50, Active, not recruiting, Sponsor: Mustafa Sahin
Phase classification: P=N/A --> P1/2 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Dec 2014
- Trial primary completion date: Walking With FES or AFO in People With MS With Foot Drop (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=24, Recruiting, Sponsor: Queen Margaret University
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2014 --> Dec 2014 Trial primary completion date: Dec 2014 --> Mar 2015